1. A clinician must match an oral mesalamine product to disease that involves the jejunum and ileum well proximal to the colon. Integrating what each delivery system does with where the disease lies, which choice will deliver active drug across the affected segment, and why?
A) An azo-bonded prodrug requiring colonic bacterial cleavage, because bacterial enzymes are abundant throughout the small intestine
B) A high-pH enteric-coated tablet releasing only at pH 7.0, because the jejunum routinely reaches pH 7.0 early in transit
C) An ethylcellulose-coated controlled-release granule preparation, because it begins releasing in the duodenum and continues throughout the small bowel and colon
D) A rectal foam preparation, because retrograde spread carries drug from the rectum to the proximal small bowel
E) A multi-matrix (MMX) once-daily tablet, because its outer coating dissolves in the stomach and floods the entire gut
ANSWER: C
Rationale:
The reasoning requires combining the release behavior of each formulation with the location of disease. Disease proximal to the colon (jejunum and ileum) needs a product that liberates active drug across the small bowel. The ethylcellulose-coated controlled-release granule preparation (for example, Pentasa) begins releasing mesalamine in the duodenum and continues continuously through the small intestine and colon, so it covers proximal small-bowel disease that colonic-targeted products miss.
Option A: Option A is incorrect: azo-bonded prodrugs depend on colonic bacterial azo-reductase, and those bacteria are concentrated in the colon, not the proximal small bowel, so the active moiety would be released distal to the disease.
Option B: Option B is incorrect: a pH 7.0 enteric coating targets the terminal ileum and proximal colon; the proximal small bowel does not reliably reach that threshold early, so most of the affected segment would be bypassed.
Option D: Option D is incorrect: rectal foam treats the distal colon and rectum, and retrograde spread does not reach the proximal small bowel.
Option E: Option E is incorrect: MMX technology is designed for slow colonic release, and its enteric coating specifically resists gastric dissolution rather than releasing in the stomach.
2. Two patients begin sulfasalazine. Patient 1 is a slow acetylator (inherits low activity of the liver enzyme that inactivates the carrier); Patient 2 is a rapid acetylator. Integrating the metabolism of the carrier with its known toxicities, which prediction is correct?
A) Patient 1 will accumulate higher sulfapyridine concentrations and is more likely to experience dose-related adverse effects, and both patients still require folic acid because the carrier impairs intestinal folate absorption regardless of acetylator status
B) Patient 2 will accumulate higher sulfapyridine concentrations and suffer more toxicity, because rapid acetylation traps the carrier in the circulation
C) Neither patient needs folic acid, because acetylator status determines folate handling and only slow acetylators are at risk
D) Patient 1 is protected from all sulfasalazine toxicity because slow acetylation prevents formation of the active moiety
E) Acetylator status changes the activity of the 5-aminosalicylic acid moiety, so Patient 1 will have reduced anti-inflammatory efficacy
ANSWER: A
Rationale:
This requires combining the pharmacogenetics of the carrier with its two separate consequences. The sulfapyridine carrier is inactivated by hepatic N-acetyltransferase; slow acetylators clear it less efficiently, accumulate higher concentrations, and therefore experience more of the dose-related sulfapyridine adverse effects. Separately, sulfapyridine competitively impairs intestinal folate absorption, a hazard that does not depend on acetylator status, so both patients require folic acid supplementation.
Option B: Option B is incorrect: it reverses the pharmacogenetics—rapid acetylators clear the carrier faster and accumulate less, not more.
Option C: Option C is incorrect: folate malabsorption is a property of the carrier independent of acetylator phenotype, so both patients need supplementation.
Option D: Option D is incorrect: acetylation governs clearance of the carrier, not formation of the active 5-aminosalicylic acid moiety, so slow acetylation does not abolish toxicity—it increases carrier-related toxicity.
Option E: Option E is incorrect: acetylator status affects the sulfapyridine carrier, not the activity of the 5-aminosalicylic acid moiety, so anti-inflammatory efficacy is not reduced in slow acetylators.
3. A patient with left-sided ulcerative colitis is partially controlled on oral mesalamine. Applying the principle that clinical benefit in ulcerative colitis tracks with mucosal 5-aminosalicylic acid concentration at the inflamed segment, which adjustment is the most rational next step and why?
A) Stop oral mesalamine and rely on a rectal suppository alone, because a suppository alone reaches the splenic flexure
B) Replace mesalamine with systemic prednisone, because raising the systemic steroid level is the most direct way to increase mucosal drug concentration
C) Add an oral thiopurine, because it will immediately raise mucosal 5-aminosalicylic acid concentration
D) Switch to sulfasalazine, because the sulfapyridine carrier increases mucosal 5-aminosalicylic acid delivery beyond what mesalamine achieves
E) Add a rectal mesalamine enema to the oral therapy, because combining routes raises mucosal drug concentration across the left colon more than either route alone
ANSWER: E
Rationale:
The integrating principle is that ulcerative colitis response correlates with mucosal 5-aminosalicylic acid concentration at the diseased segment. Adding a rectal enema to oral mesalamine raises drug concentration throughout the left colon beyond what either route delivers alone, which is why combined oral-plus-rectal therapy is first-line for left-sided disease and is the rational step before escalating to systemic agents.
Option A: Option A is incorrect: a suppository reaches only the rectum and distal 10 to 15 cm, not the splenic flexure, so it would not cover left-sided disease; an enema is the correct topical form here, and abandoning oral therapy lowers rather than raises total mucosal exposure.
Option B: Option B is incorrect: systemic prednisone does not act by increasing mucosal 5-aminosalicylic acid concentration, and steroids have no maintenance role, so this misapplies the stated principle.
Option C: Option C is incorrect: a thiopurine has a delayed onset of months and does not raise mucosal 5-aminosalicylic acid concentration.
Option D: Option D is incorrect: the sulfapyridine carrier prevents premature absorption but does not increase mucosal 5-aminosalicylic acid delivery beyond modern mesalamine formulations, and it adds carrier-related toxicity.
4. Budesonide's reduced systemic toxicity depends on extensive first-pass metabolism by the liver enzyme CYP3A4 (cytochrome P450 3A4). A patient on budesonide for ileocecal Crohn's disease is started on a potent CYP3A4 inhibitor (a drug that blocks this enzyme). Integrating the basis of budesonide's safety with the effect of the inhibitor, what should the clinician anticipate?
A) Budesonide systemic exposure will fall, reducing efficacy, because CYP3A4 inhibition decreases drug absorption
B) Budesonide systemic exposure will rise substantially, increasing the risk of systemic corticosteroid effects, because the inhibitor blocks the first-pass metabolism that normally limits systemic levels
C) No change in budesonide exposure, because budesonide is eliminated unchanged by the kidney and does not depend on CYP3A4
D) Budesonide will be converted to an inactive prodrug, eliminating both local and systemic effects
E) The local anti-inflammatory effect will disappear while systemic exposure stays the same
ANSWER: B
Rationale:
Budesonide's systemic-safety advantage rests on extensive first-pass clearance by CYP3A4, which keeps systemic bioavailability near 10 to 15 percent. A potent CYP3A4 inhibitor removes that clearance bottleneck, so more intact drug reaches the systemic circulation and exposure rises substantially—reintroducing the systemic corticosteroid effects the formulation was designed to avoid.
Option A: Option A is incorrect: CYP3A4 inhibition reduces metabolism, not absorption, so systemic exposure rises rather than falls.
Option C: Option C is incorrect: budesonide is cleared by hepatic CYP3A4 metabolism, not by renal elimination of unchanged drug, so the interaction is clinically important.
Option D: Option D is incorrect: budesonide is an active glucocorticoid, not a prodrug awaiting activation; enzyme inhibition raises active drug levels rather than inactivating it.
Option E: Option E is incorrect: inhibiting CYP3A4 increases systemic exposure and does not selectively abolish the local effect.
5. A resident proposes managing a steroid-dependent Crohn's patient by simply continuing prednisone indefinitely. Integrating the role of corticosteroids with the onset kinetics of thiopurines, which reasoning correctly derives the better strategy?
A) Continue prednisone indefinitely, because corticosteroids both induce and maintain remission and alter the disease course favorably
B) Start a thiopurine alone and stop the steroid the same day, because thiopurines act within 48 hours and need no overlap
C) Avoid both steroids and thiopurines and use oral mesalamine for maintenance, because mesalamine has proven Crohn's maintenance efficacy equivalent to thiopurines
D) Co-initiate a thiopurine for maintenance while tapering the steroid as a bridge, because corticosteroids induce but cannot maintain remission, and the thiopurine needs 3 to 6 months to reach therapeutic effect
E) Increase the prednisone dose to the maximum tolerated and never introduce a steroid-sparing agent, because higher steroid doses prevent the need for immunomodulators
ANSWER: D
Rationale:
The correct strategy emerges from combining two facts: corticosteroids effectively induce remission but have no maintenance role and carry cumulative toxicity, while thiopurines are maintenance agents that require roughly 3 to 6 months to accumulate therapeutic active metabolites. Therefore the steroid serves as a short-term bridge that is tapered off while a co-initiated thiopurine takes over long-term maintenance. Steroid dependence is itself the trigger to introduce the steroid-sparing agent.
Option A: Option A is incorrect: corticosteroids do not maintain remission or favorably alter the natural history, so indefinite use is the error being corrected.
Option B: Option B is incorrect: thiopurines have a delayed onset of months, not 48 hours, so stopping the steroid immediately leaves the patient unprotected during the gap.
Option C: Option C is incorrect: mesalamine lacks proven efficacy for Crohn's maintenance and is not an equivalent substitute.
Option E: Option E is incorrect: escalating steroids increases cumulative toxicity and does not remove the need for a steroid-sparing agent.
6. Reasoning across the three competing pathways of 6-mercaptopurine metabolism, predict what happens to metabolite distribution in a thiopurine S-methyltransferase (TPMT) poor metabolizer given a standard dose, and the clinical consequence.
A) Loss of the methylation pathway channels more 6-mercaptopurine into the HPRT pathway, raising active 6-thioguanine nucleotides to very high levels and producing severe myelosuppression
B) Loss of the methylation pathway diverts more 6-mercaptopurine to xanthine oxidase, raising inactive thiouric acid and causing therapeutic failure without toxicity
C) The xanthine oxidase pathway is abolished, so 6-methylmercaptopurine rises and the only risk is mild hepatotoxicity
D) All three pathways shut down equally, so metabolite levels fall and the patient is undertreated
E) The HPRT pathway is selectively blocked, lowering 6-thioguanine nucleotides and increasing infection risk from underdosing
ANSWER: A
Rationale:
Integrating the pathways: TPMT normally diverts 6-mercaptopurine to inactive 6-methylmercaptopurine. In a TPMT poor metabolizer that methylation exit is largely absent, so more 6-mercaptopurine is channeled into the HPRT (hypoxanthine-guanine phosphoribosyltransferase) anabolic pathway, generating very high concentrations of active 6-thioguanine nucleotides and producing severe, potentially life-threatening myelosuppression at standard doses. This is why TPMT status is checked before dosing.
Option B: Option B is incorrect: loss of methylation increases active 6-thioguanine nucleotides, so the result is toxicity, not benign shunting to thiouric acid.
Option C: Option C is incorrect: TPMT poor metabolizers lose the methylation (TPMT) pathway, not the xanthine oxidase pathway, and 6-methylmercaptopurine falls rather than rises.
Option D: Option D is incorrect: the pathways do not shut down equally; the methylation branch is lost while the anabolic branch is amplified.
Option E: Option E is incorrect: the HPRT pathway is not blocked—it is the pathway that becomes overactive, raising rather than lowering 6-thioguanine nucleotides.
7. A patient of East Asian ancestry with completely normal thiopurine S-methyltransferase (TPMT) activity develops profound leukopenia shortly after starting standard-dose azathioprine. Integrating the two known pharmacogenomic predictors of thiopurine myelotoxicity, what is the most likely explanation?
A) The normal TPMT result was a laboratory error, because myelosuppression is impossible with normal TPMT activity
B) The patient must be non-adherent, because adherent patients with normal TPMT never develop leukopenia
C) A loss-of-function NUDT15 variant is allowing thioguanine triphosphates to accumulate, causing myelosuppression independent of TPMT status, and such variants are more common in East Asian populations
D) The azathioprine was contaminated, because no inherited factor other than TPMT affects thiopurine toxicity
The two predictors of thiopurine myelotoxicity are independent. NUDT15 (nudix hydrolase 15) inactivates thiopurine triphosphate metabolites; a loss-of-function NUDT15 variant allows those metabolites to accumulate and cause myelosuppression even when TPMT activity is entirely normal. Because NUDT15 loss-of-function variants are substantially more common in East Asian populations, this patient's profile fits NUDT15-mediated toxicity, illustrating why both genes are tested before therapy.
Option A: Option A is incorrect: a normal TPMT does not exclude myelosuppression, precisely because NUDT15 acts independently—so it is not evidence of a lab error.
Option B: Option B is incorrect: myelosuppression can occur in adherent patients with normal TPMT through the NUDT15 mechanism, so non-adherence is not required.
Option D: Option D is incorrect: NUDT15 is a second well-established inherited determinant beyond TPMT, so contamination is an unnecessary explanation.
Option E: Option E is incorrect: excess thiouric acid is an inactive catabolite and does not cause myelosuppression; the toxicity arises from accumulated active thioguanine metabolites.
8. A patient on azathioprine shows the preferential-methylation pattern (high 6-methylmercaptopurine, low active 6-thioguanine nucleotides) with rising liver enzymes and persistent disease activity. A clinician proposes adding low-dose allopurinol. Integrating the enzymatic interaction with the metabolite pattern, which statement correctly explains why this can help and what it requires?
A) Allopurinol will further raise 6-methylmercaptopurine and worsen hepatotoxicity, so it must never be combined with a thiopurine
B) Allopurinol will lower active 6-thioguanine nucleotides, so the azathioprine dose must be increased to compensate
C) Allopurinol has no effect on thiopurine metabolism and will not change the pattern
D) Allopurinol works by inducing thiopurine S-methyltransferase, so the methylation pattern resolves without any dose change
E) By inhibiting xanthine oxidase, allopurinol shifts metabolism away from methylation toward the active 6-thioguanine nucleotide pathway, correcting the unfavorable pattern, but the azathioprine dose must be cut to roughly 25 to 33 percent to avoid dangerous 6-thioguanine nucleotide accumulation
ANSWER: E
Rationale:
This integrates the xanthine oxidase interaction with the metabolite pattern. Inhibiting xanthine oxidase with low-dose allopurinol redirects 6-mercaptopurine metabolism away from the preferential-methylation route (which had produced high 6-methylmercaptopurine, hepatotoxicity, and therapeutic failure) toward the active 6-thioguanine nucleotide pathway, restoring efficacy while reducing the hepatotoxic methylated metabolite. Because this redirection sharply increases active metabolite formation, the azathioprine dose must be reduced to roughly 25 to 33 percent of the original with intensified monitoring to avoid dangerous accumulation.
Option A: Option A is incorrect: allopurinol lowers, not raises, 6-methylmercaptopurine by diverting metabolism, and the combination is used intentionally under dose reduction.
Option B: Option B is incorrect: allopurinol raises active 6-thioguanine nucleotides, so increasing the dose would cause toxicity.
Option C: Option C is incorrect: allopurinol has a major effect on thiopurine metabolism through xanthine oxidase inhibition.
Option D: Option D is incorrect: allopurinol inhibits xanthine oxidase rather than inducing thiopurine S-methyltransferase, and dose reduction is mandatory rather than unnecessary.
9. A patient on low-dose weekly methotrexate for Crohn's disease is prescribed folic acid. A trainee worries that adding folate will reverse methotrexate's benefit. Integrating methotrexate's two mechanisms with the rationale for folate, which explanation is correct?
A) Folate will indeed reverse the benefit, because both the toxic and the anti-inflammatory effects depend on dihydrofolate reductase inhibition
B) Folate reduces the toxicities driven by dihydrofolate reductase inhibition in rapidly dividing tissues (mucositis, cytopenias) without blunting efficacy, because the low-dose anti-inflammatory effect is adenosine-mediated and folate-independent
C) Folate has no effect on methotrexate toxicity and is given only out of tradition
D) Folate increases methotrexate's cytotoxicity, so it should be avoided in inflammatory bowel disease
E) Folate converts methotrexate into a more potent dihydrofolate reductase inhibitor, increasing both efficacy and toxicity
ANSWER: B
Rationale:
The key is that methotrexate's two mechanisms are separable. Its troublesome low-dose toxicities—mucositis, nausea, cytopenias—arise from dihydrofolate reductase inhibition in rapidly dividing non-immune tissues, and folate repletion mitigates exactly those effects. The low-dose anti-inflammatory benefit, however, operates through accumulation of methotrexate polyglutamates that raise extracellular adenosine, a folate-independent pathway. Because the benefit does not depend on folate antagonism, supplementation reduces toxicity while preserving efficacy.
Option A: Option A is incorrect: the anti-inflammatory effect is not driven by dihydrofolate reductase inhibition, so folate does not reverse it.
Option C: Option C is incorrect: folate meaningfully lowers methotrexate toxicity and is given for that reason.
Option D: Option D is incorrect: folate reduces, rather than increases, methotrexate toxicity.
Option E: Option E is incorrect: folate does not make methotrexate a stronger dihydrofolate reductase inhibitor; it replenishes the folate pool that the drug depletes in vulnerable tissues.
10. Methotrexate is predominantly eliminated by the kidney. A patient on weekly methotrexate develops worsening renal function. Integrating the drug's elimination route with its toxicity profile, what should the clinician anticipate and do?
A) Methotrexate clearance will increase as renal function declines, so the dose should be raised
B) Renal function has no bearing on methotrexate handling, so no change is warranted
C) Declining renal function shifts methotrexate to hepatic elimination, eliminating any cytopenia risk
D) Reduced glomerular filtration will cause methotrexate to accumulate, raising the risk of cytopenias; methotrexate is contraindicated once estimated glomerular filtration falls below about 30 mL/min/1.73m2
E) Renal impairment accelerates conversion of methotrexate to an inactive metabolite, so toxicity falls
ANSWER: D
Rationale:
Because methotrexate is cleared predominantly by the kidney, a fall in glomerular filtration reduces its elimination and causes the drug to accumulate, increasing the risk of bone-marrow suppression and cytopenias. For this reason methotrexate is contraindicated once estimated glomerular filtration falls below roughly 30 mL/min/1.73m2, and blood counts must be monitored closely as renal function changes.
Option A: Option A is incorrect: declining renal function reduces clearance, so the drug accumulates and the dose should not be increased.
Option B: Option B is incorrect: renal function is central to methotrexate elimination and toxicity risk.
Option C: Option C is incorrect: methotrexate does not switch to hepatic elimination to rescue clearance; impaired renal function raises systemic exposure and cytopenia risk.
Option E: Option E is incorrect: renal impairment does not accelerate inactivation; it slows elimination of active drug, increasing toxicity.
11. Consider two patients needing steroid-sparing maintenance: Patient 1 is a man with Crohn's disease; Patient 2 is a woman with ulcerative colitis who hopes to conceive. Integrating the disease-specific efficacy evidence with sex and reproductive considerations, which selection is most defensible?
A) Patient 1 is reasonable for methotrexate (comparable Crohn's efficacy and lower thiopurine-associated lymphoma risk in men); Patient 2 should receive a thiopurine, since methotrexate lacks proven ulcerative colitis efficacy and is teratogenic
B) Both patients should receive methotrexate, because it is equally effective in ulcerative colitis and Crohn's disease and safe in pregnancy
C) Patient 1 should receive methotrexate and Patient 2 should also receive methotrexate, because reproductive plans do not affect drug choice
D) Patient 2 is an ideal candidate for methotrexate because of its favorable pregnancy profile, while Patient 1 should avoid all immunomodulators
E) Both patients should avoid thiopurines entirely, because thiopurines are ineffective in both ulcerative colitis and Crohn's disease
ANSWER: A
Rationale:
Applying the positioning principles to two scenarios: in Crohn's disease, methotrexate and thiopurines have comparable steroid-sparing efficacy, and methotrexate is often favored in men because the thiopurine-associated non-Hodgkin lymphoma risk is higher in men—so methotrexate is reasonable for Patient 1. For Patient 2, methotrexate lacks proven efficacy in ulcerative colitis and is teratogenic, making a thiopurine the appropriate choice, especially given her plan to conceive.
Option B: Option B is incorrect: methotrexate is not effective for ulcerative colitis maintenance and is not safe in pregnancy.
Option C: Option C is incorrect: reproductive plans strongly affect drug choice given methotrexate's teratogenicity.
Option D: Option D is incorrect: methotrexate's pregnancy profile is unfavorable, not favorable, and there is no basis for withholding all immunomodulators from Patient 1.
Option E: Option E is incorrect: thiopurines are effective maintenance agents in both diseases, so avoiding them entirely is wrong.
12. A patient with Crohn's disease is started on combination therapy with azathioprine plus an anti-tumor necrosis factor (anti-TNF) biologic. Integrating the pharmacologic benefit of the combination with its principal tradeoff, which statement best guides management?
A) The combination requires no special precautions, because adding a thiopurine to a biologic does not change infection risk
B) The combination should be avoided entirely, because reducing anti-drug antibody formation has no clinical value
C) The thiopurine reduces formation of anti-drug antibodies against the biologic, improving durability of response, but combination immunosuppression raises opportunistic infection risk, so vaccination and infection screening should be addressed before and during therapy
D) The thiopurine accelerates clearance of the biologic, so the biologic dose must be doubled and no infection screening is needed
E) The combination eliminates the need to monitor blood counts, because the two agents offset each other's toxicities
ANSWER: C
Rationale:
The benefit-tradeoff integration is the point. Adding a thiopurine to an anti-TNF biologic reduces the formation of anti-drug antibodies, preserving drug levels and improving durability of response. The cost is that combination immunosuppression increases the risk of opportunistic infections (for example, Pneumocystis jirovecii pneumonia and herpes zoster), so vaccination status and infection screening should be addressed before and during therapy.
Option A: Option A is incorrect: combination immunosuppression clearly raises infection risk and does require added precautions.
Option B: Option B is incorrect: reducing immunogenicity has real clinical value by maintaining therapeutic biologic levels.
Option D: Option D is incorrect: the thiopurine reduces immunogenicity rather than accelerating clearance, and infection screening remains essential.
Option E: Option E is incorrect: blood-count monitoring is still required; the agents do not offset each other's toxicities.
13. A patient with mild ulcerative colitis is found to be glucose-6-phosphate dehydrogenase (G6PD) deficient (an inherited red-cell enzyme defect that increases vulnerability to oxidative injury). Integrating this finding with the mechanism of sulfasalazine toxicity and knowledge of 5-aminosalicylic acid formulations, which choice is most appropriate and why?
A) Start full-dose sulfasalazine, because the 5-aminosalicylic acid moiety protects red cells from oxidative stress
B) Start sulfasalazine but add folic acid, because folate supplementation prevents oxidative hemolysis in G6PD deficiency
C) Avoid all 5-aminosalicylic acid therapy, because every mesalamine product carries the same hemolysis risk as sulfasalazine
D) Start sulfasalazine at half dose, because halving the dose abolishes the sulfapyridine hemolysis risk
E) Choose a sulfapyridine-free mesalamine formulation, because the hemolysis risk derives from the sulfapyridine carrier, which a sulfa-free 5-aminosalicylic acid product avoids
ANSWER: E
Rationale:
This integrates the G6PD oxidative-hemolysis risk with the source of sulfasalazine toxicity and with formulation choices. The hemolytic hazard in G6PD deficiency comes specifically from the sulfapyridine carrier, an oxidant sulfonamide. Because modern mesalamine formulations deliver 5-aminosalicylic acid without sulfapyridine, selecting a sulfa-free product removes the offending oxidant while preserving anti-inflammatory therapy.
Option A: Option A is incorrect: the 5-aminosalicylic acid moiety does not protect red cells, and giving sulfasalazine exposes the patient to the sulfapyridine oxidant.
Option B: Option B is incorrect: folic acid addresses folate malabsorption, not oxidative hemolysis, so it does not make sulfasalazine safe in G6PD deficiency.
Option C: Option C is incorrect: sulfa-free mesalamine products do not carry the sulfapyridine-driven hemolysis risk, so abandoning all 5-aminosalicylic acid therapy is unnecessary.
Option D: Option D is incorrect: reducing the dose lowers but does not abolish exposure to the oxidant carrier, so a sulfa-free formulation is the correct solution.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.